ReviewBlood advances2018
Evaluating measurable residual disease in acute myeloid leukemia.
Review in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 159 citations in OpenAlex.
- Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.Leukemia research · 2022Trial
- Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant.Blood advances · 2021Trial
- Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission.Cancer · 2021Trial
- Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.Blood advances · 2021Trial
- Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Article
- Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.Blood immunology & cellular therapy · 2026Article
- Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis.Transplantation and cellular therapy · 2026Article
- Immunophenotypic Heterogeneity and Clonal Sweep in Acute Myeloid Leukemia Revealed by Flow Cytometry: A Case Series Study.Journal of personalized medicine · 2026Article
- Biomarkers and advances in AML-MRC: from bench to bedside.Annals of hematology · 2026Review
- Ultra-Sensitive Mutation Detection Technology in Myeloid Neoplasms: New Tools for Patient Monitoring.Journal of clinical medicine · 2026Review
- Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction.Current opinion in pharmacology · 2025Review
- Cellular automata modelling of leukaemic stem cell dynamics in acute myeloid leukaemia: insights into predictive outcomes and targeted therapies.Royal Society open science · 2025Article
- Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.British journal of haematology · 2025Review
- Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia.Annals of hematology · 2024Review
- Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy.International journal of clinical oncology · 2024Article
- Genomic breakpoint-specific monitoring of measurable residual disease in pediatric non-standard-risk acute myeloid leukemia.Haematologica · 2024Article
- MRD positivity was the poor prognostic factor for adverse-risk AML patients with allogeneic hematopoietic stem cell transplantation: a multicenter TROPHY study.Blood cancer journal · 2024Article
- Clinical significance of WT1 in the evaluation of therapeutic effect and prognosis of non-M3 acute myeloid leukemia.Cancer biology & therapy · 2023Article
- [NGS-based molecular genetics of leukemia-a powerful and decentralized approach].Pathologie (Heidelberg, Germany) · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Mounting evidence indicates that the presence of measurable ("minimal") residual disease (MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic detection, is a strong, independent prognostic marker of increased risk of relapse and shorter survival in patients with acute myeloid leukemia (AML) and can be used to refine risk-stratification and treatment response assessment. Because of the association between MRD and relapse risk, it has been postulated that testing for MRD posttreatment may help guide postremission treatment strategies by identifying high-risk patients who might benefit from preemptive treatment. This strategy, which remains to be formally tested, may be particularly attractive with availability of agents that could be used to specifically eradicate MRD. This review examines current methods of MRD detection, challenges to adopting MRD testing in routine clinical practice, and recent recommendations for MRD testing in AML issued by the European LeukemiaNet MRD Working Party. Inclusion of MRD as an end point in future randomized clinical trials will provide the data needed to move toward standardizing MRD assays and may provide a more accurate assessment of therapeutic efficacy than current morphologic measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.